Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Mathias Earl Palmer"'
Autor:
Mathias Earl Palmer, Michael H. Storandt, Jennifer Gile, Tyler J. Zemla, Tanios S. Bekaii-Saab, Zhaohui Jin, Nguyen H. Tran, Amit Mahipal
Publikováno v:
Journal of Clinical Oncology. 41:559-559
559 Background: Cabozantinib, a multikanase inhibitor, is approved by the Food and Drug Administration (FDA) for treatment of advanced stage hepatocellular carcinoma (HCC) following progression on sorafenib. The CELESTIAL study which demonstrated ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b47b1d7cb0354539ad2636c77427544
https://doi.org/10.1200/jco.2023.41.4_suppl.559
https://doi.org/10.1200/jco.2023.41.4_suppl.559
Autor:
Jennifer Gile, Mathias Earl Palmer, Michael H. Storandt, Tanios S. Bekaii-Saab, Nguyen H. Tran, Amit Mahipal
Publikováno v:
Journal of Clinical Oncology. 41:507-507
507 Background: Lenvatinib, a multikinase inhibitor, is an FDA approved treatment for advanced hepatocellular carcinoma (HCC) in the first line setting. Atezolizumab and bevacizumab are considered new standard of care as first line therapy after resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb00a1896fbbf26cd87e9e5abd950309
https://doi.org/10.1200/jco.2023.41.4_suppl.507
https://doi.org/10.1200/jco.2023.41.4_suppl.507